GSK updates share count and 4.05B voting rights
Rhea-AI Filing Summary
GSK plc (GSK) reported its share capital and voting rights position as at 31 August 2026. The issued share capital consisted of 4,316,302,379 Ordinary Shares of 31¼ pence each, of which 270,881,064 shares were held in treasury.
After excluding treasury shares, the total number of voting rights in GSK was 4,045,421,315. Shareholders may use this voting-rights figure as the denominator when assessing whether they must notify interests or changes in interests under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Positive
- None.
Negative
- None.
Key Figures
Issued share capital: 4,316,302,379 Ordinary Shares
Treasury shares: 270,881,064 Ordinary Shares
Total voting rights: 4,045,421,315
+2 more
5 metrics
Issued share capital
4,316,302,379 Ordinary Shares
Issued share capital as at 31 August 2026
Treasury shares
270,881,064 Ordinary Shares
Ordinary Shares held in Treasury as at 31 August 2026
Total voting rights
4,045,421,315
Total number of voting rights in GSK as at 31 August 2026
Ordinary Share nominal value
31¼ pence per share
Nominal value of each GSK Ordinary Share
Company registration number
3888792
Registered in England & Wales
Key Terms
Treasury Shares, Total voting rights, Disclosure Guidance and Transparency Rule 5.6.1R, Foreign private issuer
4 terms
Total voting rights financial
"Therefore, the total number of voting rights in the Company is 4,045,421,315"
The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.
Disclosure Guidance and Transparency Rule 5.6.1R regulatory
"In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R"
Foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
FAQ
What is the total number of voting rights in GSK (GSK) as of 31 August 2026?
As of 31 August 2026, GSK reported a total of 4,045,421,315 voting rights. This figure reflects issued Ordinary Shares excluding those held in treasury and is the denominator shareholders should use for UK disclosure threshold calculations.
Why did GSK (GSK) publish this total voting rights announcement?
GSK published the total voting rights information in conformity with the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R, enabling shareholders to determine if they must notify interests or changes in interests in the company.
Who signed the September 2026 GSK (GSK) total voting rights report?
The report was signed on behalf of GSK by Victoria Whyte, described as Company Secretary and Authorised Signatory for and on behalf of GSK plc, dated 1 September 2026 in London.
AI-generated analysis. How Rhea-AI works. Not financial advice.
